Skip to content

Coated Catheter vs. Needle Injection: Which Better Relieves Wrist Artery Spasm? A Clinical Comparison

Efficacy and Safety of Nitroglycerin-Coated Catheter versus Traditional Injection for Radial Artery Spasm: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129309
Enrollment
Unknown
Registered
2026-08-03
Start date
2026-08-10
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radial artery spasm

Interventions

Experimental group:nitroglycerin-coated catheter therapy
control group:traditional radial artery injection therapy

Sponsors

Nanfang Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Volunteer to sign a written informed consent form, fully understanding the research purpose, process, and potential risks; 2.Age range from 18 to 80 years old, gender is not limited; 3.Patients diagnosed with radial artery spasm (RAS) via radial artery angiography exhibit local vascular stenosis (diameter reduction =30%), significantly increased resistance to catheter advancement, or obstruction of contrast medium passage; 4.Pain at the puncture site (Visual Analogue Scale, VAS = 4) or interruption of the procedure due to spasm; 5.Hemodynamically stable (systolic blood pressure =90 mmHg and heart rate =50 beats per minute), with no severe comorbidities affecting the implementation of intervention;

Exclusion criteria

Exclusion criteria: 1.Hypersensitivity to the components of nitroglycerin; 2.individuals with severe coagulation dysfunction or a tendency towards active bleeding; 3.women in pregnancy or lactation period; 4.Patients with anatomical abnormalities such as tortuosity, calcification, or occlusion of the radial artery; 5.patients with severe hepatic and renal dysfunction, uncontrolled hypertension, or severe cardiovascular disease; 6.Recent users of potent CYP3A4 inhibitors or PDE5 inhibitors; 7.individuals with mental disorders, cognitive impairments, or those unable to cooperate with follow-up visits; 8.Patients who, according to the comprehensive assessment of the researcher, are deemed unsuitable for participation in this trial (such as those with complex conditions, short expected survival, etc.).

Design outcomes

Primary

MeasureTime frame
Rate of Successful Catheter Passage on First Attempt;

Secondary

MeasureTime frame
VAS score of spasm-related pain after intervention;Total time for catheter passing through spastic segment;Incidence of operation-related complications;

Countries

China

Contacts

Public ContactShifei Wang

Nanfang Hospital, Southern Medical University

shifeiw@qq.com+86 156 2217 6127

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026